|
The Indian Pharmaceutical Market (IPM) has registered a growth of 8.8 per cent for the month of December 2019, slipping from the 32 month high of 14.5% in November. According to AIOCD AWACS report, the IPM has recorded sales of Rs.1,40,223 crore and a growth of 9.8 per cent for Moving Annual Total (MAT) basis during December 2019.
Among the top 50 corporates, 26 corporates exhibited double digit growth, while 4 of the top 50 corporates exhibited degrowth for the month of December 2019.
Among the top 10 corporates, Torrent exhibited the highest growth of 14 per cent, followed by Alkem at 13.8 per cent, Intas at 12.2 per cent, Mankind at 11.6 per cent and Zydus at 11.4 per cent. While the rest of the top ten companies have grown at single digit.
Among the 11-20 ranked corporates, Dr. Reddy's shows the highest growth of 22.8 per cent, followed by Aristo at 22.6 per cent and Emcure at 17.2 per cent. While 2 companies in single digit and one company reflecting negative growth.
Amongst the 21-30 ranked corporates, FDC exhibited highest growth 12.8 per cent followed by Franco at 12.4 per cent and Cadila at 10.4 per cent. While three corporates reflecting negative growths.
Amongst the 31-40 ranked corporates, Boehringer Ingelheim exhibited the highest growth 31.9 per cent followed by La Renon at 24.3 per cent, and Meyer Organics at 16 per cent. 6 of the 10 corporates growing in double digit.
Amongst the 41-50 ranked corporates, Corona Remedies exhibited the highest growth 26.7 per cent, followed by Medley 18.3 per cent and Wallace at 16.4 per cent
Amongst the 51-60 ranked corporates, Pharmed exhibited a growth of 23.4 per cent, followed by Centaur with 16.6 per cent, Fresenius Kabi growth 6.9 per cent 3 corporates growing in single digit, while five corporate reflecting negative growth.
Amongst the 61-70 ranked Corporates, Koye Pharma exhibited the highest growth 29.5 per cent, followed by Eli Lilly at 28 per cent and Danone at 24 per cent 3 of the corporates at single digit growth and 2 reflecting degrowth.
Amongst the 71-80 ranked corporates, Leeford HC exhibited the highest growth 40.9 per cent followed by Samarth at 17.6 per cent, East India growing at 16.5 per cent.
Amongst the 81-90 ranked corporates, TTK exhibited the highest growth 7.9 per cent, followed by Modi Mundi at 6.9 per cent and Unimed TL at 4.9 per cent.
Amongst the 91 -100 ranked corporates, Alniche LS exhibited the highest growth 33.3 per cent, followed by Unison at 18.3 per cent and P&G Health at 11 per cent.
Amongst the 101 -150 few of the corporates exhibited double digit growths are Indiabulls Pharma, Brinton Pharma, Paviour, Reckitt Benckiser, Elan, MSN, J&J, Entod, Linux Labs, Dabur, Juggat, DWD, Stadmed, Icon, Finecure Pharma, Icpa Healthcare, Yash Pharma, Comed, Celon Labs and Innovcare are the top 20.
Among the top 10 companies, Zydus, Mankind, Alkem, Torrent, Intas and Ranbaxy registered double digit growth, while Sun Pharma, Cipla, Lupin and Abbott Healthcare registered single digit growth.
For the month of December, multinational companies exhibited a growth of 5.2 per cent, 7.7 per cent for the quarter. and 9.3 per cent for the MAT period. While the Indian companies exhibiting 9.7 per cent for the month, 9.9 per cent for the quarter and 9.9 per cent for the MAT.
Amongst the top multinational companies, Boehringer Ingelheim 31.9 per cent exhibited the highest growth followed by Reckitt and Benckiser 28.7 per cent and Eli Lilly at 28 per cent.
FDC related market showed negative growth of 45 per cent, while the Approved FDC market showed a growth of 9.5 per cent and the single molecules growth are at 8.6 per cent for the month 28 per cent.
The non-FDC component growth drivers are volumes at 0.6 per cent, prices at 5.9 per cent, while new introduction exhibits a high growth of 3 per cent.
Among the top brands, Mixtard has maintained the top position for the month of December 19. While Lantus has lost a position and moved to no.3 position, while Glycomet-GP has regained no.2 position. Janumet has moved up to no.4 position and Augmentin to No.5 position.
Few major brands who have dropped in ranks are Phensedyl Cough Linctus (-3), Istamet (-8), PanD (-6), Volini (-2), Sinarest (-3), Shelcal (-3).
There were 247 (454 SKUs) brands launched in the month of December 19, which has added Rs.17.33 crore incremental sales in the market.
From therapy (Super Group) perspective on MAT basis, 7 of the 20 therapies are reflecting a growth in double digit. Highest among that being Stomatologicals 16.9% followed by Urology 14.6 per cent, blood related 13.4 per cent and anti-diabetic at 12.6 per cent, Sex stimulants 12.2 per cent, Cardiac 11.7per cent.
Anti Infectives 9.2 per cent, vitamins and minerals 9.1 per cent, gynaecology 8.3 per cent, anti-neoplastic 8.9 per cent and Opthal 8.4per cent and gastro 8.2 per cent are showing lower growths, vaccines 5.3 per cent and anti-malarials 6.4 per cent are the slow growing.
From the regional perspective, 13 of the regions are above the IPM growth of 8.8 per cent and 17 regions below the IPM. 13 regions reflecting double digit growth. North Karnataka (22 per cent), South Maharashtra (21.4%), Bihar (19.3 per cent), Jharkhand (17.8 per cent) and North Maharashtra (16.6 per cent) are the top 5 regions in terms of growth.
|